SINGAPORE -- As the new coronavirus spreads across the globe and devastates communities, companies are racing to develop a vaccine, with the U.K.'s Emergex becoming the latest to divert resources from other projects, including the development of a dengue fever vaccine, to work on COVID-19.
The startup expects to have a vaccine ready for testing within two months, Lim Xinhong, director and analyst at Singapore-based venture capital firm Vickers Venture Partners told DealStreetAsia. Vickers Venture is an investor in Emergex.
